PRINCETON, N.J., March 25, 2019 /PRNewswire/ -- Sandoz today announced the US availability of Treprostinil Injection, the first fully substitutable AP rated generic version of Remodulin ®* ...
RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an ...
RESEARCH TRIANGLE PARK, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Treprostinil Injection, a generic form of ...
Patients with pulmonary arterial hypertension will shortly have a more convenient way to treat their disease. United Therapeutics and DEKA Research & Development have received the Food and Drug ...
In a recent press release, Medtronic announced that it has received U.S. Food and Drug Administration (FDA) approval for the Implantable System for Remodulin® (ISR) to treat patients with pulmonary ...
Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...
RESEARCH TRIANGLE PARK – United Therapeutics Corp. (Nasdag:UTHR) has received approval from the U.S. Food and Drug Administration (FDA) of its New Drug Application (NDA) for the use of Remodulin ...
Jan. 17, 2006 — Tolcapone tablets have been reintroduced in the UK market after a 7-year suspension by the European Medicines Evaluation Agency; the European Commission has approved orphan drug status ...
MORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of Remodulin®, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback